DXS International plc : Trading Statement Thomson Reuters



The Directors of DXS International plc, the developer and supplier of clinical decision support systems to Clinical Commissioning Groups and healthcare professionals, have noted the adverse movement in its share price today.  The Company is not aware of any business reason why the share price should be so affected. 

The Company continues to trade successfully and in line with management expectations and is progressing towards full rollout approval under GPSoC which is anticipated to be achieved within the second quarter of 2015. Revenue continues to improve and it is anticipated that revenue for the year ending 30th April 2015 will be in excess of £2.4 million, an improvement of approximately 33 per cent on the year ending 30th April 2014

The Company also has a healthy pipeline of new business and the Board remains confident that the business will continue to grow

The Directors of DXS International plc accept responsibility for this announcement.


David Immelman, CE0

DXS International plc


01252 719800
City & Merchant Ltd (Corporate Adviser)
David Papworth
020 7101 7676

MB Communications (Financial PR)
Maxine Barnes 07860 489571

About DXS:

DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively which should significantly contribute towards the NHS achieving its projected efficiency savings.

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DXS International plc via Globenewswire